Sun Pharma launches Xelpros in US

Xelpros is indicated in the treatment of Open-angle Glaucoma or Ocular Hypertension. Sun Pharma in-licensed Xelpros from SPARC in June 2015.

Jan 12, 2019 05:01 IST India Infoline News Service

Sun Pharma
Sun Pharma on Friday said that it has launched Xelpros in the US markets. In September 2018, Sun and its research arm Sun Pharma Advanced Research Company Ltd (SPARC) had received USFDA approval for their novel drug Xelpros (Latanoprost ophthalmic emulsion).

Xelpros is indicated in the treatment of open-angle glaucoma or ocular hypertension. Sun Pharma in-licensed Xelpros from SPARC in June 2015 and the USFDA approval triggered a milestone payment of $10mn to SPARC. Further, with Xelpros sales kicking in, SPARC will also receive sales royalties going forward.

This is the second NDA approval for SPARC’s R&D pipeline. For Sun Pharma, this is a good start for the year. Last year, the company received USFDA EIR for its Halol facility after years of struggle and received an Elepsia approval in December 2018.

Sun is trying to build up its specialty products in dermatology, oncology, and ophthalmology in the US and has several products lined up for launches going ahead.
Drug Indication Current status
Absorica Acne Already launched: Nearing patent expiry
Levulan Kerastick Actinic Keratose Already launched: Nearing patent expiry
Elepsia XR Epilepsy Approved in December 2018
Cequa Dry Eye Approved in August 2018
Illumya Epilepsy Approved in March 2018; launched in October 2018
Bromsite Eye care Launched in November 2016
Kapspargo Sprinkle Heart failure Launched in August 2018
Yonsa Prostate Cancer Approved in May 2018
Odomzo Basal Cell Carcinoma Bought from Novartis in December 2016
Seciera Dry Eye Currently in Phase trials

Related Story